Immune checkpoint inhibitors for hepatocellular carcinoma - A game changer in treatment landscape

Area of Science:

• Hepatobiliary cancers
• Medical oncology
• Immunotherapy

Background:

• The treatment landscape for advanced hepatocellular carcinoma (HCC) has evolved rapidly.
• Multikinase inhibitors (MKI) and antiangiogenic targeted therapies have been central to HCC research.
• Single-agent immune checkpoint inhibitors (ICI) demonstrated efficacy, leading to approvals in second-line settings.

Purpose of the Study:

• To review the development of immune checkpoint inhibitors (ICI) alone and in combination for advanced HCC.
• To discuss the potential impact of these therapies across all stages of HCC.
• To examine safety concerns and future directions for ICI-based combinations in HCC treatment.

Main Methods:

• Narrative review of clinical studies and approvals.
• Analysis of efficacy data for ICI monotherapy and combination regimens.
• Evaluation of safety profiles and emerging treatment strategies.

Main Results:

• The combination of atezolizumab and bevacizumab represents a paradigm shift, showing a 30% objective response rate and 19.2 months median survival in first-line advanced HCC.
• ICI-based combinations are emerging as a significant advancement in HCC treatment.
• Further ICI-based combinations are anticipated for approval.

Conclusions:

• Immune checkpoint inhibitors (ICI), both as single agents and in combination, are transforming advanced HCC treatment.
• ICI-based combinations offer improved efficacy and a favorable toxicity profile, impacting all stages of HCC.
• Future research will likely focus on optimizing ICI combinations and exploring their broader application in HCC management.